SEC Company Response from Forma Therapeutics Holdings, Inc. (CIK 0001538927) — Jun 16, 2020
Forma Therapeutics Holdings, Inc. (CIK 0001538927)
Date: June 16, 2020 · CIK: 0001538927 · Accession: 0001193125-20-170375
AI Filing Summary & Sentiment
File numbers found in text: 333-238783
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Re: Forma Therapeutics Holdings, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-238783
Dear Sir/Madam:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several Underwriters, wish to advise you that approximately 2,100 copies of the Preliminary Prospectus included in the Registration Statement on Form S-1 were distributed during the period June 15, 2020 through the date hereof, to prospective underwriters, institutions, dealers and others.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
In accordance with Rule 461 of the Act, we hereby join in the request of Forma Therapeutics Holdings, Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 p.m. Eastern Time on June 18, 2020, or as soon thereafter as practicable.
[Remainder of page intentionally left blank]
Very truly yours,
By:
Show Raw Text
CORRESP 1 filename1.htm CORRESP Jefferies LLC 520 Madison Avenue New York, New York 10022 SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010-3629 June 16, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Forma Therapeutics Holdings, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-238783 Dear Sir/Madam: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several Underwriters, wish to advise you that approximately 2,100 copies of the Preliminary Prospectus included in the Registration Statement on Form S-1 were distributed during the period June 15, 2020 through the date hereof, to prospective underwriters, institutions, dealers and others. We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. In accordance with Rule 461 of the Act, we hereby join in the request of Forma Therapeutics Holdings, Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 p.m. Eastern Time on June 18, 2020, or as soon thereafter as practicable. [Remainder of page intentionally left blank] Very truly yours, By: JEFFERIES LLC By: /s/ Dustin Tyner Name: Dustin Tyner Title: Managing Director By: SVB LEERINK LLC By: /s/ Irina Melnikova Name: Irina Melnikova, Ph.D. Title: Managing Director By: CREDIT SUISSE SECURITIES (USA) LLC By: /s/ John Hoffman Name: John Hoffman Title: Managing Director, ECM